



Dr Banu Kaya joined Barts Health NHS Trust, London, UK as a consultant haematologist based within the departments of Paediatric Haematology/Oncology and Clinical Haematology in 2007. She became honorary Clinical Senior Lecturer, Barts and The London School of Medicine and Dentistry, Queen Mary University of London in 2014. Dr Kaya currently jointly leads the haemoglobinopathy services at Barts Health. Dr Kaya led the paediatric component of the National Haemoglobinopathy Peer Review Programme and co-chaired the steering group, 2014-2016. She remains a member of the steering group for the 2019-20 peer review.

Dr Kaya was appointed to the haemoglobinopathies Clinical Reference Group (CRG) in 2019.

Dr Kaya was the North East London Haematology Training Programme Director (2008-2014) and Chair of the Training Programme Management Committee, North East Central London, 2014. She has a number of postgraduate and undergraduate teaching responsibilities and is a member of the Royal College of Paediatrics and Child Health (RCPCH) teaching faculty. Dr Kaya was co-opted as a Trustee of the British Society of Haematology (BSH) in 2018 and elected as an Ordinary Trustee in 2019. She is on the board of Directors. She is a member of the BSH paediatric haematology special interest group (SIGG). Dr Kaya has been the UK Chief Investigator for two international clinical trials and Principal Investigator for over six recent clinical trials. She has contributed to a number of recent National guidelines (UK standards for the clinical care for adults with sickle cell in the UK, 2018, standards for the clinical care of children and adults with thalassaemia in the UK, 2016, BSH hydroxycarbamide guidelines 2018, BSH chelation guidelines 2019).